With CMS closing its public comment period for its draft decision to limit coverage of Biogen’s Aduhelm last week, two Big Pharma companies developing similar Alzheimer’s drugs got in their comments just before Thursday’s deadline.
Eli Lilly and Roche both posted lengthy letters to the CMS...
